Aortic insufficiency in continuous-flow left ventricular assist device support patients is common but does not impact long-term mortality

详细信息    查看全文

• 作者：Christopher T. Holley ; MD^a ; ¹ ; Megan Fitzpatrick ; BA^a ; ¹ ; Samit S. Roy ; MSPH^b ; M. Chadi Alraies ; MD^b ; Rebecca Cogswell ; MD^b ; Laura Souslian ; MD^a ; Peter Eckman ; MD^c ; Ranjit John ; MD^a ; ^{johnx008@umn.edu}
• 关键词：aortic insufficiency ; aortic regurgitation ; circulatory support device ; heart failure ; outcomes ; surgery (complications)
• 刊名：The Journal of Heart and Lung Transplantation
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：36
• 期：1
• 页码：91-96
• 全文大小：364 K
• 卷排序：36

文摘

Aortic insufficiency (AI) is a significant long-term complication of continuous-flow left ventricular assist device (CF-LVAD) implantation. We sought to evaluate its impact on clinical outcomes and mortality in CF-LVAD recipients.MethodsWe retrospectively analyzed 237 patients implanted with HeartMate II CF-LVADs at our institution from June 2005 through June 2013. We evaluated recipients’ baseline characteristics and annual echocardiograms, grading AI severity as either none, trace, mild, moderate or severe. Only moderate or severe AI was considered clinically significant. Recipients who underwent concomitant aortic valve surgery or who had undergone previous prosthetic aortic valve implantation were excluded.ResultsModerate or severe AI occurred in 32 (15.2%) patients. Risk factors that significantly affected the development of AI included older age at the time of implantation, female gender, longer duration of LVAD support and destination therapy designation. Freedom from moderate or severe AI was 94%, 76% and 65% of patients at 1, 3 and 5 years, respectively. Overall cohort survival based on Kaplan-Meier analysis was 78%, 59% and 42% at 1, 3 and 5 years, respectively. There was no difference in survival between recipients who developed significant AI and those who did not (log-rank test, p = 0.73).ConclusionsIn this large, single-institution study, the overall rate of AI was low, but increased in frequency with longer duration of LVAD support. Although AI development remains a concern for patients on long-term CF-LVAD support, AI development does not appear to impact long-term mortality.